Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "A Phase 3 LAGOON Study - Lurbinectedin Alone or in Combination With Irinotecan vs. Investigator's Choice (Topotecan/Irinotecan) for Relapsed SCLC"

150 views
July 9, 2023
Comments 0
Login to view comments. Click here to Login